Compare BLNK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | FHTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 247.1M |
| IPO Year | N/A | 2020 |
| Metric | BLNK | FHTX |
|---|---|---|
| Price | $0.69 | $5.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $2.13 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 7.6M | 157.8K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,631,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $40.89 |
| Revenue Next Year | $17.87 | $11.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $2.95 |
| 52 Week High | $2.65 | $6.79 |
| Indicator | BLNK | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.85 | 62.02 |
| Support Level | $0.77 | $5.25 |
| Resistance Level | $0.85 | $5.95 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 3.47 | 68.11 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.